Mylan refuses to testify at Senate hearing about EpiPen rebates to Medicaid

(By Ed Silverman for STAT)

In a move that angered a key Senate lawmaker, Mylan Pharmaceuticals has declined to testify at a planned Nov.30 Senate hearing to review a $465 million settlement the drug maker purportedly reached with the US Department of Justice for shortchanging Medicaid. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.